Taysha Gene Therapies (TSHA) Projected to Post Earnings on Tuesday

Posted by Brenda Bartman on Oct 27th, 2026

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) will likely be posting its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Taysha Gene Therapies to announce earnings of ($0.1286) per share and revenue of $0.76 million for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 8:30 AM ET.

Taysha Gene Therapies (NASDAQ:TSHA – Get Free Report) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.02). On average, analysts expect Taysha Gene Therapies to post ($0.52) EPS for the current fiscal year and ($0.49) EPS for the next fiscal year.

Taysha Gene Therapies Price Performance

TSHA opened at $4.01 on Tuesday. The stock has a fifty day moving average price of $4.98 and a 200 day moving average price of $5.33. The company has a current ratio of 17.76, a quick ratio of 17.76 and a debt-to-equity ratio of 0.13. Taysha Gene Therapies has a 1 year low of $3.45 and a 1 year high of $7.30. The stock has a market cap of $1.31 billion, a price-to-earnings ratio of -9.55 and a beta of 1.19.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on TSHA shares. The Goldman Sachs Group raised their price target on Taysha Gene Therapies from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Tuesday, July 21st. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of Taysha Gene Therapies in a research note on Tuesday, June 30th. Citizens Jmp restated a “market outperform” rating and issued a $11.00 price objective on shares of Taysha Gene Therapies in a report on Thursday, July 2nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, September 21st. Finally, Robert W. Baird raised their price objective on shares of Taysha Gene Therapies from $12.00 to $15.00 and gave the company an “outperform” rating in a research report on Tuesday, June 30th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average price target of $12.77.

Check Out Our Latest Stock Analysis on Taysha Gene Therapies

About Taysha Gene Therapies

(Get Free Report)

Taysha Gene Therapies, Inc is a clinical-stage biotechnology company focused on developing gene therapies for severe monogenic diseases of the central nervous system. The company uses adeno-associated virus (AAV) delivery technologies and other genetic medicine approaches to address disorders that currently have limited or no effective treatment options.

Taysha’s development programs have included TSHA-102 for Rett syndrome, TSHA-101 for GM1 gangliosidosis and TSHA-120 for giant axonal neuropathy.